New Stock News | Jiangxi Biopharmaceutical IPO prospectus invalid
Jiangxi Biological Products Research Institute Co., Ltd. (hereinafter referred to as "Jiangxi Biological") submitted its Hong Kong IPO prospectus on October 26, 2025, which expired after 6 months on April 26, 2026. China International Capital Corporation and CMB International Securities acted as its joint sponsors at the time of submission.
Jiangxi Biological Products Research Institute Co., Ltd. (hereinafter referred to as "Jiangxi Biological") submitted a Hong Kong stock prospectus on October 26, 2025, which expired on April 26, 2026, after being valid for 6 months. CICC and CMSC International were its joint sponsors when submitting the application.
According to the prospectus, Jiangxi Biological is the largest provider and exporter of tetanus antitoxin for human use ("human TAT") in China, and it is also a comprehensive anti-serum platform with an integrated industry chain.
Related Articles
Shui On Land (00272) plans to conduct international bond offerings to institutional investors in Asia and Europe.
STANCHART (02888) will distribute a final dividend of HK$3.83746 per share on May 14th.
IMPRO PRECISION (01286) achieved a total revenue of HK$1.4276 billion in the first quarter, a year-on-year increase of 22.5%.
Shui On Land (00272) plans to conduct international bond offerings to institutional investors in Asia and Europe.
STANCHART (02888) will distribute a final dividend of HK$3.83746 per share on May 14th.
IMPRO PRECISION (01286) achieved a total revenue of HK$1.4276 billion in the first quarter, a year-on-year increase of 22.5%.
